However, promising anti-tumor activity was reported with the combination of tiragolumab and atezolizumab in the GO30103 study, with a confirmed objective response rate of 46% in the subset of patients with PD-L1-positive NSCLC [13]. Here, CD274 is linked to neoplasm.